IDEAYA BIOSCIENCES ANNOUNCES POSITIVE DATA FROM PHASE 1/2 COMBINATION TRIAL OF IDE397, A POTENTIAL FIRST-IN-CLASS MAT2A INHIBITOR, AND TRODELVY® IN MTAP-DELETION UROTHELIAL CANCER
IDEAYA BIOSCIENCES INC - MANAGEABLE SAFETY PROFILE IN IDE397 AND TRODELVY TRIAL
Source text: ID:nPn7LdYz9a
Further company coverage: IDYA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.